Download this short summary slideset of key takeaway points from a live presentation on integrating CAR T-cell therapy into management of patients with hematologic malignancies.
Download these slides from our live meeting series to review key strategies for integrating CAR T-cell therapy into your management of patients with hematologic malignancies.
With the approval of lisocabtagene maraleucel, another CAR T-cell therapy option is now available for patients with relapsed/refractory lymphomas. Review this expert commentary on how to incorporate this agent into your practice.
Listen to Noopur Raje, MD, answer audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy.
Download this slideset for key insights from our podcast featuring expert answers to questions on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy.
Listen to Frederick L. Locke, MD, answer audience questions from a live CCO Webinar focused on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with lymphomas.
In this interactive on-demand Webcast, expert faculty members discuss how they currently use CAR T-cells to treat hematologic malignancies and provide a look ahead at new data and promising agents that may soon change practice.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.